ArticlemedRxiv : the preprint server for health sciences2025
Wearable Myoelectric Interface for Neurorehabilitation (MINT) to Recover Arm Function: a Randomized Controlled Trial.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03401762 (Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
23 authors.
Funding
Abstract
Background: Abnormal muscle co-activation contributes to arm impairment after stroke. This single-blind, randomized, sham-controlled trial evaluated the feasibility and efficacy of home-based, personalized myoelectric interface for neurorehabilitation (MINT) conditioning to reduce abnormal co-activation and enhance arm function and determine the optimal number of abnormally co-activating muscles to target during training. Methods: Moderately to severely impaired chronic stroke survivors were randomized to one of three MINT groups (who played customized games requiring independent activation of 2 or 3 abnormally co-activating muscles) or a sham control group (played using one muscle). All groups trained 90 minutes/day, 5 days/week at home and 1 day/week in lab, for 6 weeks, and changed trained muscle sets every 2-3 weeks. The primary outcome was the Wolf Motor Function Test (WMFT) at 6 weeks. Results: Fifty-nine participants completed the training. Participants performed 315 ± 85 (mean ± SD) repetitions daily. At week 6, participants in all MINT groups combined improved by 4 s on WMFT (p=0.0008), exceeding the minimal clinically important difference (1.5 s). Participants who trained 3 muscles simultaneously improved by 6.8 s (p=0.001), while the 2-muscle and sham groups did not change significantly. In per-protocol analysis, the 3-muscle group, but not 2-muscle groups, improved significantly more than sham (p=0.046), though not in intention-to-treat analysis. All MINT groups continued improving at 4 weeks post-training. Importantly, severely impaired participants in combined MINT groups improved more than those in sham (p=0.02). Importantly, combined MINT groups also improved their reaching range of motion significantly more than sham. Co-activation decreased by 76% in MINT groups during training. Notably, reduction in co-activation during reaching correlated significantly with improved arm function and range of motion. Other secondary outcomes did not show clinically important improvement. Stroke involving the posterior limb of the internal capsule negatively predicted response to MINT. Conclusions: Home-based MINT conditioning, especially the 3-muscle variant, is feasible, reduces co-activation, and improves arm movement and function. Clinical Trial Registration―: ClinicalTrials.gov (NCT03401762).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.